Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case–Cohort Study on Italian Women: Results from the Moli-sani Study
- 18 October 2020
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 121 (04), 449-456
- https://doi.org/10.1055/s-0040-1718531
Abstract
Background Elevated levels of key enzymes of the fibrinolytic system, such as tissue plasminogen activator (tPA), are reported as predictors of poor outcome in cancer patients. Limited information is available about their potential predictive value for breast cancer (BC) risk in the general population. Aim We examined the association of tPA levels with BC risk in a case–cohort study including women from the prospective Moli-sani cohort. Methods A sample of 710 women (mean age: 54.6 ± 12.1 years) was selected as a subcohort and compared with 84 BC cases, in a median follow-up of 4.2 years. Incident cases of BC were validated through medical records. tPA plasma levels were measured using an enzyme-linked immunosorbent assay kit. Hazard ratio (HR) and 95% confidence interval (CI), adjusted for relevant covariates, were estimated by a Cox regression model using the Prentice method. Results Compared with the lowest quartile (11.2 ng/mL) had increased risk of BC (HRIVvsI: 2.20, 95% CI: 1.13–4.28) after adjusted for age, smoking, education, menopause, and residence. Further adjustment for biochemical markers did not modify this association. The risk of BC increased by 34% for each increase in 1 standard deviation of log-transformed tPA levels (p = 0.046). Elevated levels of tPA were associated mainly with estrogen-receptor-positive BC (2.08, 95% CI: 1.18–3.66). Conclusion Higher levels of tPA, reported to predict cardiovascular risk, are a potential biomarker for BC risk, supporting the hypothesis of a “common soil” linking the pathogenic mechanisms of hormone-dependent tumors and cardiovascular disease. A.F, L.I., M.B.D, and M.M. contributed to the concept and design of the work and interpretation of data; S.G. and L.R. performed the tPA measurements; S.C., A.D.C. S.G., L.R., M.M., T.P., and M.P. managed data collection; S.C. analyzed the data and reviewed the manuscript; R.P. wrote the manuscript; C.C., M.B.D., A.F., G.d.G., and L.I. originally inspired the research and critically reviewed the manuscript. * [Supplementary Appendix A] lists all the Moli-sani Investigators. Received: 08 May 2020 Accepted: 02 September 2020 Article published online: 18 October 2020 © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyFunding Information
- HYPERCAN Study (AIRC “5xMILLE” no. 12237)
- POR FESR (459 del 27/11/2018)
- Pfizer Foundation
- Italian Ministry of University and Research (1588)
- Instrumentation Laboratory
- Italian Ministry of Health (RF-2018-12367074)
This publication has 27 references indexed in Scilit:
- Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR studyBMJ Open, 2013
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Platelets, coagulation and fibrinolysis in breast cancer progressionBreast Cancer Research, 2013
- Distribution of short and lifetime risks for cardiovascular disease in ItaliansEuropean Journal of Preventive Cardiology, 2011
- White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI projectHaematologica, 2011
- Circulating thrombotic and haemostatic components in patients with coronary artery diseaseIndian Journal of Clinical Biochemistry, 2010
- Tissue-Type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significanceBreast Cancer Research and Treatment, 2005
- Plasminogen activation and cancerThrombosis and Haemostasis, 2005
- Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease – a 13-year follow-upThrombosis and Haemostasis, 2003
- Concentration of Endogenous tPA Antigen in Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1998